IRulya Therapeutics Inc.
IRLA· Nasdaq
IRLAIRulya Therapeutics Inc.
Filed May 13, 2024 · 10-Q · 43 days after period end · 0000950170-24-058201
| Metric | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|
| Net Income | -$11.15M | -$12.25M | -$21.64M | -$23.09M |
| EPS Diluted | -$0.26 | -$0.34 | -$0.72 | -$0.78 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IRulya Therapeutics Inc. · CIK 1662774 · Engraved from SEC EDGAR
ended Mar 31, 2024 · filed May 13, 2024 · 43 d after period end
